Fig 4. Antiviral prophylactic rates in patients with positive of hepatitis B surface antigen (n = 134) undergoing chemotherapy in different cancer types.
The rates of antiviral prophylaxis in doctors treating lung, breast and colorectal cancers were significantly lower in doctors treating hematological cancers (all p < 0.05).